Sep. 4, 2013, 7:49 AM
- C.R. Bard (BCR) will acquire Rochester Medical (ROCM) for $20/ share.
- The deal "greatly enhances BCR's position in a $930 million global urology homecare market," management says. ROCM had net sales of $61.68M last year. (PR)
- It's a good day to be an ROCM shareholder — the purchase price represents a nearly 45% premium from Tuesday's close.
- ROCM +43.7% premarket
- Last month: BCR acquires Medafor for $200M
Aug. 19, 2013, 8:39 AM
Jun. 28, 2013, 11:29 AMC.R. Bard (BCR +1%) say sold certain assets of its Electrophysiology division to Boston Scientific (BSX +1.6%) for $275M in cash. BCR's Electrophysiology division manufactures and markets medical equipment, catheters and accessories used in cardiac electrophysiology procedures. Annual net sales linked to the divested assets totaled aoound $111M in 2012. The company expects the sale to be about $0.05 dilutive to 2013 EPS and immaterial to 2014 guidance previously provided. | Comment!
Dec. 20, 2011, 5:03 PMC.R. Bard (BCR) acquires Lutonix - a privately-held medical device developer currently conducting an FDA-approved investigational device exemption trial using drug-coated balloons for the treatment of peripheral arterial disease - for $225M, plus an additional $100M upon PMA approval of the device. | Comment!
Oct. 25, 2011, 4:43 PM
BCR vs. ETF Alternatives
CR Bard Inc manufactures, distributes and sells medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, and extended care facilities.
Other News & PR